600216.SH
浙江医药
SSE · Healthcare · Drug Manufacturers - Specialty & Generic · CN
CNY 12.55
−5.14%Year over year
Reported trailing growth
- Revenue
- -6.0%
- EBITDA
- —
- EBIT
- -48.3%
- EPS
- -48.6%
- Free cash flow
- +42.6%
- Operating cash flow
- +11.7%
Forward estimates
Based on analyst estimates
- Revenue
- -0.4%
- EBITDA
- +15.8%
- EPS
- +36.7%
Three-year CAGR
- Revenue
- +3.0%
- EBITDA
- +14.0%
- EBIT
- +24.0%
- Net income
- +17.4%
- EPS
- +17.6%
- Free cash flow
- +169.5%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Mar 1, 2026